Editas Medicine Inc EDIT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 08/12/22 EDT
18.77UNCH (UNCH)
Volume
42,867
Close
18.77quote price arrow up+0.68 (+3.76%)
Volume
1,443,068
52 week range
9.59 - 73.03
Loading...
  • Open18.41
  • Day High19.03
  • Day Low17.83
  • Prev Close18.09
  • 52 Week High73.03
  • 52 Week High Date09/02/21
  • 52 Week Low9.59
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap1.29B
  • Shares Out68.74M
  • 10 Day Average Volume1.75M
  • Dividend-
  • Dividend Yield-
  • Beta2.05
  • YTD % Change-29.3

KEY STATS

  • Open18.41
  • Day High19.03
  • Day Low17.83
  • Prev Close18.09
  • 52 Week High73.03
  • 52 Week High Date09/02/21
  • 52 Week Low9.59
  • 52 Week Low Date06/14/22
  • Market Cap1.29B
  • Shares Out68.74M
  • 10 Day Average Volume1.75M
  • Dividend-
  • Dividend Yield-
  • Beta2.05
  • YTD % Change-29.3

RATIOS/PROFITABILITY

  • EPS (TTM)-2.70
  • P/E (TTM)-6.96
  • Fwd P/E (NTM)-5.36
  • EBITDA (TTM)-179.99M
  • ROE (TTM)-34.20%
  • Revenue (TTM)31.80M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-580.16%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date11/07/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Editas Medicine Inc

There is no recent news for this security.

Profile

MORE
Editas Medicine, Inc. is a clinical-stage gene editing company. The Company is focused on developing transformative gene editing medicines to treat a range of serious diseases. It has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1...
James Mullen
Executive Chairman of the Board
Gilmore O Neill
President, Chief Executive Officer, Director
Michelle Robertson
Chief Financial Officer, Executive Vice President
Bruce Eaton Ph.D.
Executive Vice President, Chief Business Officer
Mark Shearman Ph.D.
Executive Vice President, Chief Scientific Officer
Address
11 Hurley St
Cambridge, MA
02141-2110
United States

Top Peers

SYMBOLLASTCHG%CHG
MRUS
Merus NV
25.04-0.01-0.04%
RETA
Reata Pharmaceuticals Inc
21.02+0.06+0.29%
KDNY
Chinook Therapeutics Inc
20.64+0.65+3.25%
MDGL
Madrigal Pharmaceuticals Inc
73.34+3.13+4.46%
VERV
Verve Therapeutics Inc
35.59+1.80+5.33%